259 related articles for article (PubMed ID: 32012202)
1. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
Hjorth M; Dandu N; Mellergård J
PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
3. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
[TBL] [Abstract][Full Text] [Related]
5. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
[TBL] [Abstract][Full Text] [Related]
6. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
Paolicelli D; Manni A; D'Onghia M; Direnzo V; Iaffaldano P; Zoccolella S; Di Lecce V; Tortorella C; Specchia G; Trojano M
J Neuroimmunol; 2017 Feb; 303():75-80. PubMed ID: 28043652
[TBL] [Abstract][Full Text] [Related]
8. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
[TBL] [Abstract][Full Text] [Related]
10. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
Blumenfeld-Kan S; Staun-Ram E; Miller A
Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
Huber JE; Chang Y; Meinl I; Kümpfel T; Meinl E; Baumjohann D
J Immunol; 2020 Mar; 204(5):1101-1110. PubMed ID: 32034063
[TBL] [Abstract][Full Text] [Related]
14. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.
Dominguez-Villar M; Raddassi K; Danielsen AC; Guarnaccia J; Hafler DA
J Autoimmun; 2019 Jan; 96():40-49. PubMed ID: 30122421
[TBL] [Abstract][Full Text] [Related]
17. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
18. Increased Percentage of CD8
Houston TW; Howlett-Prieto Q; Regenauer C; Testai FD; Yao F; Feng X; Reder AT
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36535763
[TBL] [Abstract][Full Text] [Related]
19. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
20. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
Sato DK; Nakashima I; Bar-Or A; Misu T; Suzuki C; Nishiyama S; Kuroda H; Fujihara K; Aoki M
J Neuroimmunol; 2014 Mar; 268(1-2):95-8. PubMed ID: 24507619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]